Abstract: Previous studies have suggested that macrophage migration inhibitory factor (MIF) -173G/C polymorphism may be associated with cancer risk. However, previous research has demonstrated conflicting results. Therefore, we followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and the meta-analysis on genetic association studies checklist, and performed a meta-analysis to investigate the association between MIF -173G/C polymorphisms and the risk of cancer. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were combined to measure the association between MIF promoter polymorphisms and cancer risk. The pooled ORs were performed for the dominant model, recessive model, allelic model, homozygote comparison, and heterozygote comparison. The publication bias was examined by Begg's funnel plots and Egger's test. A total of ten studies enrolling 2,203 cases and 2,805 controls met the inclusion criteria. MIF (-173G/C) polymorphism was significantly associated with increased cancer risk under the dominant model (OR=1.32, 95%, CI=1.00-1.74, P=0.01) and the heterozygote comparison (OR=1.38, CI=1.01-1.87, P=0.04). In subgroup analysis, MIF polymorphism and prostate were related to increased risk of prostate and non-solid cancer. In conclusion, MIF polymorphism was significantly associated with cancer risk in heterozygote comparison. The MIF -173G/C polymorphism may be associated with increased cancer risk.
Introduction
Macrophage migration inhibitory factor (MIF) was first identified nearly 50 years ago and has been used as a cytokine and an enzyme. 1, 2 MIF is a member of the transferring growth factor-β (TGF-β) super family, which is expressed by a broad variety of cells, including B-and T-lymphocytes as well as endocrine, endothelial, and epithelial cells of diverse histogenetic origin. 3 Presently, MIF is considered to play an important role in the pro-and anti-inflammatory response to infection since it is constitutively expressed and acts as an upstream regulator of many other inflammatory cytokines. 4, 5 Recently, several studies have shown that MIF can promote tumor growth and viability by modulating immune responses and supporting tumor-associated angiogenesis. 6 A few experiments suggested that MIF mRNA and MIF protein are overexpressed in a number of cancers. 7 Tan et al reported that MIF is upregulated in patients with pancreatic cancer and causes dysfunction of insulin secretion in β-cells. 8 Krockenberger et al reported that MIF is clearly overexpressed on the protein level in invasive cervical cancer compared to cervical dysplasia. 9 Two polymorphisms in the promoter region of MIF have been reported in the past. One is a single nucleotide polymorphism (SNP) 
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Zhang et al at the nucleotide position -173 (G to C) 10 and the other is a tetranucleotide CATT repeat beginning at position -794.
11
The association between these two polymorphisms and diseases has been extended to several inflammatory conditions including Graves' disease, 12 idiopathic thrombocytopenic purpura, 13 and Vogt-Koyanagi-Harada (VKH) syndrome. 14 These studies indicate that these two polymorphisms of MIF are associated with inflammatory diseases. Similarly, some studies have reported that the polymorphism of MIF resulted in an increased risk of cancer. With new studies about the polymorphism of MIF and the risk of cancer emerging, there has been no meta-analysis conducted regarding the association between MIF promoter polymorphism and the risk of cancer in recent times. The aim of this study is to perform a meta-analysis of all available studies that analyze the association between the polymorphism of MIF promoter and the risk of cancer.
Materials and methods literature search
The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement ( Figure S1 ) and the meta-analysis on genetic association studies checklist ( Figure S2 ) were followed in our meta-analysis. A comprehensive search of EMBASE, PubMed, Web of Science, OVID, Cochrane Library, and China National Knowledge Infrastructure (CNKI) was done from database inception to July 22, 2014 without language restriction. The search strategy was "macrophage migration inhibitory factor or MIF" and "polymorphism or variant or muta tion or genotype." To complete our research, we also studied the review articles and references of retrieved articles manually. The literature review was performed independently by X Zhang and J Wang and the disagreements were resolved through consensus by all the authors. 15, 16 selection criteria
Studies were included in the meta-analysis if the following inclusion criteria were satisfied: 1) case-control studies focused on association between the MIF promoter polymorphism and cancer risk, 2) studies enrolled more than 30 patients, 3) studies provided sufficient data to estimate the odds ratio (OR) and 95% confidence intervals (CIs) according to MIF promoter polymorphism, and 4) when study patients overlapped with patients in other included studies, we selected the first study published. The two researchers (J Wang and X Zhang) independently read the titles and abstracts and excluded the uncorrelated studies; then the full-texts were examined by our review team. The studies were selected according to the inclusion criteria.
15,16
Data abstraction 
Results

Characteristics of identified studies
Following an initial search, 166 studies were retrieved from PubMed; 233 studies from EMBASE; 313 studies from OVID; 266 studies from Web of Science; 50 studies from Cochrane Library; 532 studies from CNKI; and five additional review articles were added to make our search comprehensive. After duplicated records were removed, 
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MiF polymorphism and cancer risk 878 published studies were identified. We excluded 780 unrelated studies by reading the titles and abstracts. Next, we downloaded the full-text of the remaining 98 studies and excluded 65 unrelated studies. Of the remaining 33 studies considered for performing the meta-analysis, some studies were found to report incomplete data or report other associations between MIF and cancer. We tried our best to communicate with the first and corresponding authors to get the necessary data. Some authors were able to provide the necessary data for our study, while others did not. Ultimately, after further reviewing in detail, ten studies were included in our meta-analysis. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Figure 1 shows in detail the selection process. These ten studies were published between 2005 and 2014. There were 2,203 cases and 2,805 controls included in our meta-analysis. Studies were carried out in People's Republic of China, Taiwan, Japan, Iran, Italy, and USA. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used in seven studies. 17, 18, 20, 21, 23, 25, 26 One study used polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP). 24 The other two studies employed denaturing high-performance liquid chromatography (DHLPC) wave analysis 19 and a Genetic Analyzer, 22 respectively. Three studies assessed prostate cancer; 20, 22, 26 three studies assessed leukemia 17, 19, 25 and one each for gastric cancer, 24 cervical cancer, 18 colorectal cancer, 21 and bladder cancer. 23 The genotype distribution in one study deviated from HWE. 26 The main characteristics of all the included studies are listed in Table 1 .
Meta-analysis
Overall, ten prospective studies enrolling 2,203 cases and 2,805 controls were included in our meta-analysis. A statistically significant association between MIF (-173G/C) polymorphism and cancer risk was found under the dominant model (OR=1.32, CI=1.00-1.74, P=0.01) ( Table S1 presents the results of overall and subgroup analyses.
sensitivity analysis
We performed sensitivity analysis by omitting one study at a time and calculating the pooled ORs again. However, the results did not show any significant statistical differences when studies were omitted. Therefore, the stability of the study was not influenced by any individual study. Table S2 presents the sensitivity analysis in the dominant model.
Publication bias
Both Begg's funnel plot and Egger's test were carried out to evaluate the publication bias of the studies. The results are presented in Figure 3 and 
Discussion
In our meta-analysis, ten studies enrolling 2,203 cases and 2,805 controls were included. The results indicated that MIF -173G/C polymorphism was significantly associated with cancer risk. MIF is known as a major regulator of inflammation and a central upstream mediator of innate immune response, and functions as a key mediator to counter-regulate the inhibitory effects of glucocorticoids within the immune system. 27 There are numerous studies suggesting that MIF polymorphism might be associated with the risk of immune disease. Liu et al reported that MIF polymorphism is associated with new-onset Graves' disease in a Taiwanese Chinese population. 12 Hao et al carried out a meta-analysis to investigate the association between MIF polymorphism and the risk of inflammatory bowel disease (IBD). 28 They found that MIF -173G/C polymorphism contributed to the susceptibility of IBD.
MIF is also involved in cancer growth and progression. The elevated MIF and mRNA levels have been observed in many tumor cells and pre-tumor states. Krockenberger et al found that MIF was significantly overexpressed on both the protein level and the mRNA level in invasive cervical cancer and MIF protein was overexpressed in SiHA and CaSki cervical cancer cell lines. 9 Huang et al reported that MIF expression levels in hepatocellular carcinoma tissues and cell lines were significantly up-regulated compared with adjacent normal tissues or a normal liver cell line. 29 Moreover, several studies suggested that MIF polymorphism might be associated with the risk of cancer. Only one study reported that MIF -173G/C polymorphism is associated with a decreased risk of cancer. 23 All the other studies reported the opposite conclusion. We also found a meta-analysis that investigated the association between the MIF -173G/C polymorphism and cancer risk. 30 However, there were only five studies included in that meta-analysis, and the result was only under the dominant model. In recent times, some new studies have been emerging; for instance, Yuan et al reported that MIF -173G/C polymorphism is associated with submit your manuscript | www.dovepress.com
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Zhang et al decreased cancer risk. 23 This conclusion contradicted with the conclusion in the previous meta-analysis. Therefore, we added new studies in our meta-analysis and calculated ORs in the dominant model, recessive model, homozygote comparison, heterozygote comparison, and allelic model. In our meta-analysis, we found that MIF -173G/C polymorphism is significantly associated with cancer risk in the dominant model (OR=1.32, 95% CI 1.00-1.74, P=0.01) and heterozygote comparison (OR=1.38, 95% CI 1.01-1.87, P=0.04). There were no significant associations between MIF -173G/C polymorphism and cancer risk in the recessive model (OR=0.98, 95% CI 0.67-1.45, P=0.93), homozygote comparison (OR=1.02, 95% CI 0.64-1.63, P=0.93), and allelic model (OR=1.32, 95% CI 1.00-1.74, P=0.05). Drawing from these results, we conclude from our meta-analysis that MIF -173G/C polymorphism might increase the risk of cancer.
There are several limitations in our meta-analysis. First, publication bias exists in the current meta-analysis. If the future studies find that MIF polymorphism was not associated with cancer risk, then publication bias might cause false outcomes. Second, there were some studies lacking in necessary data to calculate ORs under different genetic models. Although we had tried our best to communicate with the first and corresponding authors, some were unable to reply. Third, the patients included in the meta-analysis were limited. It was difficult for us to perform subgroup analyses and obtain specific results. Additionally, only papers published in English or Chinese were included in our meta-analysis, and 
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MiF polymorphism and cancer risk eligible studies written in other languages that could have fulfilled our study criterion were not included.
Conclusion
Our meta-analysis concluded that MIF -173G/C polymorphism might increase the risk of cancer. Given the above limitations, more studies are needed to confirm the association between MIF polymorphism and the risk of cancer.
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Zhang et al NA eligibility criteria 6 specify study characteristics (eg, PicOs, length of follow-up) and repo rt characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale.
Literature search and selection criteria
information sources 7 Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies)
in the search and date last searched.
Literature search
and selection criteria search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Literature search and selection criteria study selection 9 state the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data abstraction
Data collection process 10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11
List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.
Statistical analysis risk of bias in individual studies
12
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Data abstraction
summary measures 13 state the principal summary measures (eg, risk ratio, difference in means).
Statistical analysis
synthesis of results
14
Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, I
2 )
for each meta-analysis.
Statistical analysis
risk of bias across studies 15 specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies).
Statistical analysis (Continued)
PRISMA 2009 For each study, present characteristics for which data were extracted (eg, study size, PicOs, follow-up period) and provide the citations. Table S1 risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Table 2 and Figure 3 results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Figure 2 Figures S1-S4
21
Present results of each meta-analysis done, including confidence intervals and measures of consistency. Table S2 risk of bias across studies
22
Present results of any assessment of risk of bias across studies (see item 15). Table 2 additional analysis Provide full details of the search strategy employed; outline the full electronic search strategy -specific combination of keywords and any limits applied-for at least one database. specify whether synonyms of polymorphisms/genes (eg, snP number) were searched. If the meta-analysis identifies an association within a subgroup of the population studied but not another, discuss the implications of these results, and if applicable the possibility of subgroup-specific publication bias. 
Figure 3 and
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. 
